Navigation Links
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Date:6/30/2008

al benefit of an add-on therapy in PAH patients who are already receiving an approved background therapy. The study population consisted of 235 patients who were optimized on an approved oral therapy for PAH, either bosentan (Tracleer(R)), an endothelin receptor antagonist, or sildenafil (Revatio(R)), a phosphodiesterase-5 inhibitor. The majority of patients were New York Heart Association (NYHA) Class III (~98%) of varied etiologies, including idiopathic or familial PAH (~60%), collagen vascular disease associated PAH (~30%), and PAH associated with HIV, anorexigens or other associated conditions (~10%).

The primary efficacy endpoint of the TRIUMPH-1 clinical trial was the change in six-minute walk (6MW) distance at 12 weeks measured at peak exposure, defined by the trial protocol as 10-60 minutes after administration of ITRE relative to baseline. Analysis of the TRIUMPH-1 clinical trial results confirmed an improvement in median 6MW distance of approximately 20 meters (p<0.0005 at peak exposure, Hodges-Lehmann estimate and non-parametric analysis of covariance in accordance with the trial's pre-specified statistical analysis plan), in patients receiving ITRE as compared to patients receiving only background therapy. In addition, the 6MW distance at week 12 relative to baseline at trough exposure was also significantly improved, with an estimated treatment effect of approximately 14 meters (p<0.007). Secondary endpoints related to quality of life and change in NT pro-BNP, a plasma biomarker of cardiac function, were also significantly improved in the ITRE group as compared to the group receiving only background therapy (p<0.05). Other secondary efficacy measures, including change in Borg Dyspnea Score (shortness of breath test), NYHA functional class, signs and symptoms score, and time to clinical worsening, were not significantly different between the ITRE and background therapy only groups. Safety findings were typically those associated with the well-know
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
2. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
3. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
4. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
5. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
6. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
7. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
8. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
11. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... Dec. 17, 2014  IGI Laboratories, Inc. (NYSE MKT: ... of its offering of $125 million aggregate principal amount ... The Notes were offered and sold only to qualified ... Act of 1933, as amended (the "Securities Act"). ... of 3.75% per year, payable semiannually in arrears on ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ) ... Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... a lot of progress in the past few ... accepted in high-reliability environments, and are even starting ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... (Nasdaq: MYL ) today commented on a ruling ... Sunovion Pharmaceuticals Inc. in relation to Sunovion,s Brovana ® ... New York granted Sunovion,s motion regarding one of Sunovion,s defenses ... in today,s ruling and believes the Court erred in its ...
... March 2, 2012  Arena Pharmaceuticals, Inc. (NASDAQ: ... a Marketing Authorization Application (MAA) with the European Medicines ... for weight control, including weight loss and maintenance of ... or patients who are overweight (BMI >27) and have ...
Cached Medicine Technology:Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 2Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 3Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 4
(Date:12/15/2014)... (PRWEB) December 15, 2014 Kathy McAfee, ... prestigious Women World Awards in the category of Best ... gold award for her weekly career blog Networking ... advice to help professionals elevate their talent and influence ... blog, named after her book Networking Ahead for Business, ...
(Date:12/15/2014)... December 15, 2014 In support ... bring attention to restrictive state laws that may ... on this important area of public health policy. ... Compromise the Integrity of Independent Review, contends that ... of independent peer review determinations can result in ...
(Date:12/15/2014)... Bacteroides is becoming the indicator of choice for assessing sewage ... coliforms, it cannot reproduce in the presence of oxygen so ... of the new Bacteroides Sewage Screen:, ... positives from coliforms naturally occurring in the environment , ... the same sampling method with results as quick as 24hrs ...
(Date:12/15/2014)... For the second year in a row, ... Coffees of 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak ... at number 10. This is the first year that any ... is ranked on quality, value, and other aspects, including certifications ... of 100, and at $17.99 for 12-ounces, was also the ...
(Date:12/15/2014)... Following on the heels of its successful ... gearing up for another round of holiday cheer. , ... marijuana dispensaries, began the 2014 holiday shopping season with ... weekend. , “We've picked up a lot of ... Station CEO and founder, Ryan Fox. , And as ...
Breaking Medicine News(10 mins):Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2Health News:Colorado’s Grass Station Helps Holiday Shoppers Put Something Special under the Christmas Tree 2
... Solar I, which has thus far spilled 50,000 gallons of industrial ... problems// to the people in the area. The ship had sunk ... that many people have fallen sick and one man has died ... and respiratory problems are the main complaints from the people so ...
... More than 2,000 people are being recruited from Orkney, Scotland ... to identify genes that cause osteoporosis. //The study is to ... Sanday, Stronsay and Shapinsay, as well as those from the ... as volunteers. The study may cost ?240,000 over the next ...
... has been conducted by researchers from the University of Michigan ... //7 months after therapy lived longer. ,According to ... Southwest Oncology Group and led by researchers at the U-M ... 20th issue of the Journal of Clinical Oncology, has explained ...
... only the diseased organs or cells - for example, cancer ... cancer cells and release their contents with the help of ... into the tumour cell. They did this by putting the ... tumour cells where it gets “unpacked” with the help of ...
... A new version of the free and popular Access Grid ... Laboratory, is now available for download. //The Access Grid Toolkit ... enable distributed researchers to work together as if they were ... in its third release, with more than 20,000 downloads across ...
... on smoking in public places would worsen health inequalities for ... BMJ.// ,Smoking is the largest single cause of preventable ... people dying of smoking related diseases in 2002, and more ... smoking. ,The Health Act 2006 will make all ...
Cached Medicine News:Health News:New Study To Identify Osteoporosis Genes 2Health News:PSA Can Predicts The Treatment Response In Advanced Prostate Cancer 2Health News:Microcapsules target cancer cells 2Health News:Microcapsules target cancer cells 3Health News:Latest Enhancements to the Free Access Grid Toolkit Now Available 2Health News:Latest Enhancements to the Free Access Grid Toolkit Now Available 3Health News:Mental Health Units Should not be Exempt from Smoking Ban 2
... Remels newest member of the Xpect family, ... A and B in one rapid test. The ... are available in 20 minutes. ,The Remel Xpect ... wide range of rapid, direct specimen tests that ...
Inquire...
Inquire...
Inquire...
Medicine Products: